OMCL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

313.39M

+2.12%

0.489

-18.54%

281.29M

+4.31%

0.313

+20.33%

302.33M

+4.05%

0.441

-1.9%

Estimates Revision

The market is revising Upward the revenue expectations for Omnicell, Inc. (OMCL) for FY2025, with the revenue forecasts being adjusted by 2.93% over the past three months. During the same period, the stock price has changed by 32.15%.

Revenue Estimates for FY2025

Revise Upward

+2.93%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.77%

In Past 3 Month

Stock Price

Go Up

+32.15%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast OMCL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 40.67 USD with a low forecast of 34.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 42.630

Low

34.00

Averages

40.67

High

45.00

Current: 42.630

Low

34.00

Averages

40.67

High

45.00

Benchmark

Buy

maintain

$45 -> $50

2025-12-09

Reason

Benchmark

Price Target

$45 -> $50

2025-12-09

maintain

Buy

Reason

Benchmark raised the firm's price target on Omnicell to $50 from $45 and keeps a Buy rating on the shares after the company unveiled Titan XT, an enterprise version of its XT automated dispensing system that integrates with OmniSphere, the company's new cloud-based, HITRUST-certified medication management platform. The firm thinks the market is responding well to Omnicell's approach of providing options like XTExtend, rather than only offering a next generation connected cabinet, says the analyst, who contends that the market is "moving to a major adoption curve of connected devices and will lift all boats."

BofA

Allen Lutz

Neutral

maintain

$36 -> $46

2025-12-09

Reason

BofA

Allen Lutz

Price Target

$36 -> $46

2025-12-09

maintain

Neutral

Reason

BofA analyst Allen Lutz raised the firm's price target on Omnicell to $46 from $36 and keeps a Neutral rating on the shares after the company announced yesterday the release of a new cabinet and held a virtual Q&A session at the American Society of Health-System Pharmacists Midyear Clinical Meeting. At first glance, the firm came away incrementally optimistic and sees an opportunity for Omnicell to modestly improve the growth arc in late 2026 and beyond with a cabinet refresh/upgrade cycle, the analyst tells investors in a research note. The firm added that it is increasing its 2026 and 2027 revenue/EBITDTA estimates slightly and raising the multiple to reflect optionality for firmer growth on the back of a new cabinet cycle.

Benchmark

NULL -> Buy

maintain

$40 -> $45

2025-10-31

Reason

Benchmark

Price Target

$40 -> $45

2025-10-31

maintain

NULL -> Buy

Reason

Benchmark raised the firm's price target on Omnicell to $45 from $40 and keeps a Buy rating on the shares. Omnicell's Q3 upside and Q4 guidance provide further evidence that the XTExtend and Amplify product offerings launched late last year are gaining increasing traction, the analyst tells investors.

Piper Sandler

Overweight

downgrade

$57 -> $55

2025-08-11

Reason

Piper Sandler

Price Target

$57 -> $55

2025-08-11

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Omnicell to $55 from $57 and keeps an Overweight rating on the shares. The firm notes the company raised 2025 guidance on Q2 strength across both segments and a dynamic China tariff situation. Piper updates its product gross margin forecast for the second half of 2025 and 2026 to reflect management's latest commentary and the expectation that mitigation efforts eliminate effectively all China tariff impact by Q4 2026.

Wells Fargo

Stan Berenshteyn

Overweight

maintain

$37 -> $40

2025-07-21

Reason

Wells Fargo

Stan Berenshteyn

Price Target

$37 -> $40

2025-07-21

maintain

Overweight

Reason

Wells Fargo analyst Stan Berenshteyn raised the firm's price target on Omnicell to $40 from $37 and keeps an Overweight rating on the shares. The firm raises its 2025 adjusted EBITDA estimate above guided midpoint on a more favorable tariff setup post-90 day pause than we previously contemplated.

BofA

Neutral

downgrade

$34 -> $32

2025-07-14

Reason

BofA

Price Target

$34 -> $32

2025-07-14

downgrade

Neutral

Reason

BofA lowered the firm's price target on Omnicell to $32 from $34 and keeps a Neutral rating on the shares. BofA appreciates Omnicell's leading position in a duopolistic pharmacy automation market, but limited visibility into components of product revenue growth creates uncertainty near-term, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Omnicell Inc (OMCL.O) is 24.88, compared to its 5-year average forward P/E of 31.47. For a more detailed relative valuation and DCF analysis to assess Omnicell Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

31.47

Current PE

24.88

Overvalued PE

43.11

Undervalued PE

19.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

19.56

Current EV/EBITDA

13.07

Overvalued EV/EBITDA

26.98

Undervalued EV/EBITDA

12.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.82

Current PS

1.62

Overvalued PS

4.46

Undervalued PS

1.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OMCL News & Events

Events Timeline

No data

News

2.0

12-10NASDAQ.COM

Phibro Animal Health Shares Surge 59.6% Year-to-Date: What’s Behind the Rise?

6.5

12-10NASDAQ.COM

Should You Keep NEOG Stock in Your Portfolio at This Time?

9.0

12-09NASDAQ.COM

RMD Stock Poised for Growth Following FDA Approval of AI-Driven Smart Comfort

People Also Watch

Frequently Asked Questions

What is Omnicell Inc (OMCL) stock price today?

The current price of OMCL is 42.63 USD — it has decreased -2.8 % in the last trading day.

What is Omnicell Inc (OMCL)'s business?

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

What is the price predicton of OMCL Stock?

What is Omnicell Inc (OMCL)'s revenue for the last quarter?

Omnicell Inc revenue for the last quarter amounts to 310.63M USD, increased 9.99 % YoY.

What is Omnicell Inc (OMCL)'s earnings per share (EPS) for the last quarter?

Omnicell Inc. EPS for the last quarter amounts to 0.12 USD, decreased -36.84 % YoY.

What changes have occurred in the market's expectations for Omnicell Inc (OMCL)'s fundamentals?

How many employees does Omnicell Inc (OMCL). have?

Omnicell Inc (OMCL) has 3670 emplpoyees as of December 15 2025.

What is Omnicell Inc (OMCL) market cap?

Today OMCL has the market capitalization of 1.97B USD.